Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of HJB647 in Chronic Stable Heart Failure With Reduced Ejection Fraction
NCT07465653Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of HJB647 in heart failure with reduced ejection fraction (HFrEF) (3 arms), sponsored by Novartis. Primary endpoints: Number of participants with Adverse Events up to 33 days and Number of participants with clinically significant changes in vital signs up to 33 days. Started Mar 2026; status: recruiting.
02
Drugs
HJB647
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT07465653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07465653.